Business
ERMA: Sharp revenue decline and deepening losses in H1 2025 amid US transition and PMTA focus
ERMA: Sharp revenue decline and deepening losses in H1 2025 amid US transition and PMTA focus
About this update from Enorama Pharma Ab
Revenue dropped sharply in H1 2025 due to a US distributor change, with losses deepening from higher PMTA costs, inventory write-downs, and currency effects. New financing and a fresh US commercial strategy aim to restore growth from September.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.